Tolonen AC, Beauchemin N, Bayne C, Li L, Tan J, Lee J, et al
DUPIXENT is a clear to slightly opalescent, colorless to pale yellow solution in a: Single-dose pre-filled syringe with needle shield as: Single-dose pre-filled pen as: DUPIXENT is contraindicated in patients who have known hypersensitivity to dupilumab or any excipients of DUPIXENT [see Warnings and Precautions (5.1)]
Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight
doi:10.1007/s12035-017-0550-2 100
The MHRA recommends switching to a non-oral contraceptive method (such as an IUD, implant, or injection) or adding a barrier method (such as condoms) for 4 weeks after starting and after every dose escalation
Contact your healthcare provider immediately if you experience severe muscle pain with dark urine, signs of dehydration such as dizziness or decreased urination, persistent gastrointestinal symptoms, or any unexplained severe weakness or fatigue
